Citizens Raises Papzimeos Sales Forecast After Precigen Q3 Results
Citizens raised its price target on Precigen after the company reported a better-than-expected third-quarter result led by sales of its RRP drug. The supplied body is truncated before the revised target details.
Precigen (PGEN) was on investors’ radar on Thursday, after the biotech firm reported a better-than-expected third-quarter print led by sales of its recurrent respiratory papillomatosis (RRP) drug, prompting Citizens to raise its price target on the stock.Citizens raised PGEN’s price target to $12 f…